Company Filing History:
2 out of 81 
1 out of 23 
1 out of 3 Years Active: 2018-2022
Title: Thomas Schulz: Innovator in Viral Therapeutics
Introduction
Thomas Schulz is a prominent inventor based in Hannover, Germany. He has made significant contributions to the field of antiviral agents, particularly through his innovative research and development of labyrinthopeptin derivatives. With a total of 2 patents, Schulz's work is paving the way for new treatments for infectious diseases.
Latest Patents
Schulz's latest patents include "Labyrinthopeptins as anti-viral agents" and "Immune suppressor and its use." The first patent focuses on novel labyrinthopeptin derivatives that are effective against various infectious diseases, including those caused by human respiratory syncytial virus (RSV), Kaposi sarcoma-associated herpesvirus (KSHV), and hepatitis C virus (HCV). These derivatives not only serve as potential treatments but also aid in analyzing the mode of action of labyrinthopeptins. The second patent introduces a new binder molecule that acts as an immune suppressor, targeting the CD45 molecule and altering the immune response in individuals.
Career Highlights
Throughout his career, Thomas Schulz has worked with esteemed institutions such as the Medical School of Hannover and the Helmholtz Centre for Infection Research. His research has been instrumental in advancing our understanding of viral infections and developing therapeutic strategies.
Collaborations
Schulz has collaborated with notable colleagues, including Martin Messerle and Mark Brönstrup. These partnerships have enhanced his research efforts and contributed to the success of his innovative projects.
Conclusion
Thomas Schulz is a dedicated inventor whose work in antiviral therapeutics is making a significant impact in the medical field. His innovative patents and collaborations highlight his commitment to advancing healthcare solutions.